Navigation Links
Metabasis Therapeutics Presents Results of Preclinical Studies for,MB07811, Its Novel Product Candidate for the Treatment of,Hyperlipidemia, at the Endocrine Society's Annual Meeting

d costly chronic diseases. By applying our proprietary technologies and scientific expertise, including unique capabilities for targeting the liver and liver pathways, the Company has established a pipeline that includes preclinical and clinical product candidates targeting metabolic diseases such as diabetes, hyperlipidemia and obesity, as well as liver diseases such as hepatitis and primary liver cancer. Metabasis has developed several proprietary technologies for use in discovering and optimizing drugs, including the NuMimetic(TM) and HepDirect(R) technologies. Metabasis is continuing to identify and develop new product candidates using its proprietary technologies and expertise.

Forward-Looking Statements:

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the pre-clinical and clinical trial results, potential safety and efficacy and further development of MB07811. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause Metabasis' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, the progress and timing of development for Metabasis' product candidates; the fact that positive results obtained during early development do not necessarily mean later development will succeed; serious adverse side effects of, or serious adverse events related to, Metabasis' product candidates or proprietary technologies; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing Metabasis' product candidates; the potential and progress of pre-clinical compounds and programs; and other factors discussed in the "Risk Factors" section of Metabasis' Quarterly Report on Form 10-Q for the year ended March 31, 2007
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
2. Metabasis Therapeutics to Present Poster at American Association for Cancer Research
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:9/22/2014)... Thoratec Corporation (NASDAQ: THOR ), ... to save, support and restore failing hearts, announced today ... President and Chief Executive Officer, effective immediately.  Mr. Grossman succeeds ... from his executive and Board roles but will remain ... quarter of 2016.  Mr. Grossman has ...
(Date:9/22/2014)... -- Research and Markets  has announced the addition ... 2014" report to their offering. ... a professional and in-depth study on the current state ... the Chinese situation. The report provides a ... and industry chain structure. The diclofenac market analysis is ...
(Date:9/22/2014)... , Sept. 22, 2014 China Nepstar Chain Drugstore ... leading retail drugstore chain in China based ... will hold its 2014 Annual General Meeting of Shareholders (the "AGM") ... will be held at the meeting room of the Company at ... Shenzhen , Guangdong Province 518054, ...
Breaking Medicine Technology:Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 2Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 3Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 4Thoratec Appoints D. Keith Grossman President And Chief Executive Officer 5Global and Chinese Diclofenac Industry Report 2014 2China Nepstar Chain Drugstore Schedules Annual General Meeting of Shareholders for October 22, 2014 2
... 9 Avinger, Inc., a medical device company ... combat peripheral artery disease, announces the enrollment of ... OcclusioN CrossiNg with thE WildCat CatheTer) clinical trial. ... study intended to evaluate the Wildcat Catheter,s ability ...
... (Nasdaq: PCYC ), a biopharmaceutical company focused ... the treatment of cancer and mediated diseases, today announced ... fiscal quarter and fiscal year ended June 30, 2010 ... 2010.  The company will conduct a conference call and ...
Cached Medicine Technology:First Patient Enrolled in 'CONNECT' Clinical Trial 2Pharmacyclics Announces Date of Fiscal Year End 2010 Financial Results and Conference Call and Presentation at Stifel Nicolaus Healthcare Conference 2
(Date:9/22/2014)... of a whole eye transplant seems futuristic, if ... the U.S. Department of Defense, researchers at University ... to someday make implantation of an entire, functional ... could be a holy grail for vision restoration," ... and grant co-recipient with colleagues at University of ...
(Date:9/22/2014)... September 22, 2014 An inventor and ... to the problem of side-sleeping. "My lower arm always ... I designed a solution to this problem," she said. ... than to have your arm 'fall asleep.'" , The ... or her side more comfortably. It avoids pain and ...
(Date:9/22/2014)... September 22, 2014. Kessler researchers have published a ... psychoeducational wellness program in people with multiple sclerosis ... mental health, perceived stress, and pain. "Development ... individuals living with MS: Description and outcomes" was ... the International Journal of MS Care ...
(Date:9/22/2014)... (HealthDay News) -- Scans of young children,s brains ... This finding could potentially allow doctors to identify ... on, preliminary research suggests. "Early identification and ... as well as most neurodevelopmental disorders," the study,s ... of child and adolescent psychiatry at University of ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Pain does not ... Pain” is a user- and reader-friendly book designed to guide ... to pain-free living. This inspirational book is written to help ... to know a way to regain a pain-free life — ... of chronic pain. , Chronic pain has become an epidemic, ...
Breaking Medicine News(10 mins):Health News:Looking ahead: Whole eye transplant under development 2Health News:Can Brain Scans Help Predict Young Children's Reading Abilities? 2Health News:Naturopathic Doctor Inspires and Guides Those Who Suffer with Chronic Pain, Pointing the Way Back to Pain-free Living 2
... Nyer Medical Group, Inc., (Nasdaq: NYER ) announced ... notifying it of its failure to maintain a minimum closing bid ... for the prior 30 consecutive business days as required by Nasdaq ... the Company has until March 15, 2010, to regain compliance with ...
... ANGELES, Sept. 21 Former House Majority leader Tom Delay, who injured ... all on the line when he and dance partner Cheryl Burke, a ... network. , , Last week, Delay was ... in Marina del Rey, Calif. headed by Dr. Robert S. Bray, Jr., ...
... , RADNOR, Pa., Sept. 21 ... today announced that its TripProtector(SM)( )insurance plans are now ... to $1 million and medical assistance services that include ... 180 countries. Most trip protection plans on the market ...
... dementia, study found , MONDAY, Sept. 21 (HealthDay News) ... people with mild memory problems will soon develop Alzheimer,s ... older people with mild cognitive impairment, and 76 others ... money management test at the start of the study ...
... Montana city, incidents fell but rose again when restrictions were ... ban smoking in bars, restaurants and other public places witness ... , The research -- which incorporated data from a total ... found at least a 17 percent reduction in heart attacks ...
... , EMERYVILLE, Calif., Sept. 21 Bionovo, Inc. (Nasdaq: ... the company received a letter from NASDAQ stating that, for the ... stock has closed below the minimum $1.00 per share requirement for ... that the company has been provided a period of 180 calendar ...
Cached Medicine News:Health News:Nyer Medical Group, Inc., Nasdaq Notification Letter 2Health News:Injured Tom Delay to Put Foot to Test in Debut of Dancing With the Stars Premiere Tonight on ABC 2Health News:HTH Worldwide Introduces Trip Protection Insurance With Major Medical Benefits 2Health News:Mishandling Money May Foreshadow Alzheimer's 2Health News:Smoking Bans Bring a Drop in Heart Attacks 2Health News:Smoking Bans Bring a Drop in Heart Attacks 3Health News:Bionovo Notified by NASDAQ of Minimum Bid Price Deficiency 2Health News:Bionovo Notified by NASDAQ of Minimum Bid Price Deficiency 3
Cloward Dowel CL18 Used for Anterior Cervical Fusion and are preserved by Freeze-dried method....
8 mm S Graftech cervical spacer....
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
... is a useful addition to ... It may be used in ... and orbital regions in all ... strength over the Leibinger Micro ...
Medicine Products: